By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

EffRx 

601 Heritage Drive
Suite 208
Jupiter  Florida  33458  U.S.A.
Phone: 561-622-0321 Fax: 561-623-5509


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Delivery





Company News
EffRx Receives U.S. Orphan Drug Designation For EX404 For Treatment Of Pediatric Polycystic Ovary Syndrome 6/10/2014 9:59:04 AM
EffRx Signs Binosto® Distribution Agreements In Russia And Africa 5/28/2014 9:06:57 AM
EffRx Signs Distribution Agreements For Binosto® In Italy, Spain And Portugal 2/4/2014 9:58:24 AM
Ascendancy Healthcare Announces Distribution Partnership With EffRx 11/4/2013 10:07:13 AM
EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome (PCOS) in Paediatric Populations 10/1/2013 10:50:19 AM
EffRx Signs Distribution Agreement With Ahn-Gook Pharmaceuticals for Binosto® for Korea 6/3/2013 10:58:14 AM
Mission Pharmacal Company and EffRx Bring New Osteoporosis Medication to the United States and Canada 4/18/2012 9:47:56 AM
FDA Approves EffRx's BINOSTO®, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution 3/14/2012 9:34:24 AM
EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form 7/11/2011 11:06:09 AM
First EffRx NDA Accepted for Filing by the FDA 5/11/2011 8:23:22 AM
12
//-->